LY-2584702

DB12690InvestigationalSmall molecule

LY2584702 has been used in trials studying the treatment of Cancer, Advanced Cancer, Renal Cell Carcinoma, Metastases, Neoplasm, and Neuroendocrine Tumors, among others.

Mechanism: Pharmacologically active on Ribosomal protein S6 kinase beta-1
Curator reviewed
Formula / weight: C₂₁H₁₉F₄N₇ · 445.426 g/mol (avg)
Code names: LY 2584702

Resolves to

Compound

UNIII4965C6W4OCAS1082949-67-4ChEMBLCHEMBL3545076PubChem25118925

Structure

InChIKeyFYXRSVDHGLUMHB-UHFFFAOYSA-NSMILESCN1C=C(N=C1C1CCN(CC1)C1=C2C=NNC2=NC=N1)C1=CC=C(F)C(=C1)C(F)(F)F

Targets

P23443RPS6KB1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with LY-2584702, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account